Clinical Trial Update: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

View source ↗

Summary

Teclistamab's expanded access treatment protocol for relapsed or refractory multiple myeloma has been approved for marketing. The sponsor is Janssen Research & …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Teclistamab (teclistamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed or Refractory Multiple Myeloma | Status: APPROVED_FOR_MARKETING